Surrozen (SRZN) Depreciation & Amortization (CF) (2020 - 2026)
Surrozen (SRZN) posted quarterly Depreciation & Amortization (CF) of $65000.0 for Q1 2026, down 77.89% year-over-year from $294000.0 in Q1 2025, and up 44.44% quarter-over-quarter from $45000.0 in Q4 2025.
Powered by 
Analysis
Surrozen (SRZN) Depreciation & Amortization (CF) (2020 - 2026) Analysis & Trends
Surrozen's Depreciation & Amortization (CF) history runs 7 years deep, the most recent figure standing at $65000.0 for Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) fell 77.89% year-over-year to $65000.0; the TTM figure through Mar 2026 stood at $307000.0 (down 76.42% YoY), while the FY2025 annual figure was $537000.0, down 61.64% from the prior year.
- Depreciation & Amortization (CF) for Q1 2026 stood at $65000.0, up from $45000.0 in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $534000.0 in Q1 2022, with the low at $45000.0 in Q4 2025.
- The 5-year median for Depreciation & Amortization (CF) is $392000.0 (2024), against an average of $347117.6.
- The sharpest annual moves came in 2023 and 2025: Depreciation & Amortization (CF) grew 4.65% in 2023, then sank 83.93% in 2025.
- Surrozen's Depreciation & Amortization (CF) stood at $523000.0 in 2022, then declined by 15.87% to $440000.0 in 2023, then sank by 36.36% to $280000.0 in 2024, then tumbled by 83.93% to $45000.0 in 2025, then surged by 44.44% to $65000.0 in 2026.
- Business Quant data shows SRZN's Depreciation & Amortization (CF) at $65000.0 in Q1 2026, $45000.0 in Q4 2025, and $60000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 40.52 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Surrozen | 263.35 Mn | 263.35 Mn | - | 51,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 51,000.00 |
| Mar 31, 2026 | 65,000.00 |
| Dec 31, 2025 | 45,000.00 |
| Sep 30, 2025 | 61,000.00 |
| Jun 30, 2025 | 137,000.00 |
| Mar 31, 2025 | 294,000.00 |
| Dec 31, 2024 | 322,000.00 |
| Sep 30, 2024 | 342,000.00 |
| Jun 30, 2024 | 386,000.00 |
| Mar 31, 2024 | 392,000.00 |
| Dec 31, 2023 | 451,000.00 |
| Sep 30, 2023 | 483,000.00 |
| Jun 30, 2023 | 495,000.00 |
| Mar 31, 2023 | 482,000.00 |
| Dec 31, 2022 | 523,000.00 |
| Sep 30, 2022 | 470,000.00 |
| Jun 30, 2022 | 473,000.00 |
| Mar 31, 2022 | 534,000.00 |
| Dec 31, 2021 | 572,000.00 |
| Sep 30, 2021 | 525,000.00 |